Stromal CD10 Expression Research Articles

A Study on Stromal Expression of CD10 Marker in Breast Carcinoma and Its Role as a Prognostic Marker in a Tertiary Care Center in South Kerala

Abstract Background and Aims: Breast cancer is one of the leading causes of mortality among women. The aim of our study is to evaluate the stromal expression of CD10 in invasive breast carcinoma and to find its relationship with other prognostic markers such as age, histopathologic grade, estrogen receptor (ER), progesterone receptor (PR), and HER2Neu status. Materials and Methods: A total of 51 cases of breast cancer were included in the study. Representative sections were taken and hematoxylin and eosin staining was done. Immunohistochemistry was performed with ER, PR, Her2neu, and CD10. Stromal expression of CD10 is positive when >10% of stromal cells show cytoplasmic and membranous positivity in invasive breast carcinoma. This will be noted and statistically analyzed with different known prognostic markers of breast carcinoma. Results: Stromal CD10 positivity was seen in 74.5% of cases (45% were strongly positive and 29.5% were weakly positive). 25.5% of cases were negative. Positivity for ER, PR, and HER2, was 58.8%, 35.3%, and 27.5%, respectively. Stromal expression of CD10 was found to be significantly associated with ER negativity (P = 0.001) and PR negativity (P = 0.001). Increasing intensity was noted with few parameters such as postmenopausal status and histologic grade but could not show statistical significance. No correlation was found between CD10 overexpression with respect to the age, tumor size, lymph node positivity status, tumor stage and HER2Neu status. Conclusions: CD10 expression correlated strongly with well-established negative prognostic markers, ER/PR negativity, and higher tumor grade, thus indicating that CD10 can be used as an independent marker indicating poor prognosis. This study highlights the role of stromal CD10 expression in predicting prognosis and the relationship with other prognostic markers. Keeping the role stroma plays in predicting prognosis and tumor response, CD10 can be included as a routine prechemotherapy marker in breast carcinoma. Further studies should be performed to see the role stroma plays in hormonal expression and the usefulness of CD10 to predict treatment failure in breast carcinomas receiving neoadjuvant therapy.

An Observational Study of Stromal CD10 Expression in Breast Carcinoma and Its Association with Clinicopathological Parameters at SMS Medical College and Hospital

Introduction: Female breast cancer is now more prevalent than lung cancer worldwide, with an estimated 2.3 million new cases worldwide, or 11.7% of all cancer cases. Breast cancer is an epithelial malignancy, but tumor microenvironment i.e. stroma plays remarkable role in invasion and metastasis. The cross talk between tumor cells and stromal cells is critical step in tumor progression as a result there is increased interest in developing novel therapies targeting the microenvironment. Aim and Objectives: To study the frequency and intensity of stromal CD10 expression in invasive breast cancer and to correlate it with various clinicopathological parameters.Materials and Methods: The study was conducted in Department of Pathology at S.M.S. Medical College, Jaipur. CD 10 expression in 70 patients diagnosed with carcinoma breast during the period of 2021-2022, assessed by immunohistochemistry and scored as negative (<10% stromal positivity), weak (10-30% stromal positivity) and strong (>30% stromal positivity) and statistically analyzed with other parameters. Results and Discussion: Out of the 70 cases, 51 (72.86%) showed CD10 positivity in the stroma, with 28 (40%) showing strongly positive and 23 (32.86%) with weakly positive results. With respect to histopathological grade (P value = 0.0234), molecular subtype (P value = 0.0006), and PR negativity (P value = 0.0480), CD10 expression in the stroma showed a positive correlation. Conclusion: The correlation between stromal expression of CD10 and histopathological grade, molecular subtype, and PR negativity was statistically significant. To confirm CD10 expression in invasive breast cancer as a predictor of overall survival rates and disease-free survival, more research is required..

Abstract A014: Role of stromal CD10 expression in progression of endometrial and endometriosis-associated cancers

Abstract Endometriosis-associated carcinomas (EACs) and endometrial malignancies have many commonalities yet their pathophysiology, particularly those with high-risk histology such as clear cell, is understudied. EACs are histologically and clinically distinct from other gynecological cancers due to their unique origin within endometriosis. The endometriotic microenvironment is uniquely hypoxic with high levels of iron due to recurrent menstrual cycling, and this iron-rich microenvironment has been linked to promoting carcinogenesis through iron-induced oxidative stress. However, the mechanism by which the endometriotic microenvironment contributes to EAC tumorigenesis and how this compares with endometrial cancer is unknown. Most of our current knowledge of EACs is built on either epidemiologic analyses or correlative studies. Additionally, most studies of the endometriotic microenvironment primarily focus on the epithelial component while the role of the stroma has been largely unexplored. Mesenchymal stem cells (MSC) are a critical component of the stromal microenvironment. Recently, we identified a key role of endometriosis derived MSCs (enMSCs) in altering ovarian clear cell carcinoma iron regulation. Interestingly, enMSCs resemble the primary endometrium derived MSCs, which suggested their role in endometrial cancer. This stromal subset is characterized by the loss of surface CD10 expression. It is known that cancer cells, particularly clear cell carcinoma (CCC), have a unique requirement for high levels of iron. We hypothesize that CD10 negative enMSCs promote growth of EAC and endometrial cancer through iron regulation. MSCs were isolated from primary human benign endometriosis, benign endometrium, or endometrial cancer. Flow cytometry was used to measure surface CD10 expression. We investigated the role of CD10 negative enMSCs on CCC iron regulation. Our results showed that CD10 negative enMSCs promote CCC growth by exporting iron through the upregulation of Hephaestin (HEPH) and Ferroportin (FPO) which then led to increase labile iron pool (LIP) in CCC cells. However, increasing the LIP does not occur with iron supplementation alone, this indicates the critical role of CD10 negative enMSCs in regulating iron handling in CCC cells. Additionally, our data showed that CD10 negative enMSCs alter the balance of Ferritin L and Ferritin H- the main iron storage proteins- in CCC cells. Mechanistically, our preliminary data showed that CD10 negative enMSCs directly donate Ferritin L into CCC cells. Further, CD10 negative enMSCs enhance Ferritin H degradation through the upregulation of ferritinophagy in CCC cells. In conclusion, our results indicate there is a sub-population of enMSCs, marked by the loss of CD10 expression, that enhances EAC and endometrial cancer cell growth through iron regulation. This highlights the existence of a tumor-promoting stromal cell within both the endometrium and endometriosis which can be capitalized on as an “Achilles' heel” to uncover novel treatment targets for EAC and endometrial cancer. Citation Format: Huda I. Atiya, Lan G. Coffman. Role of stromal CD10 expression in progression of endometrial and endometriosis-associated cancers [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr A014.

Diagnostic significance of CD10 marker to differentiate colorectal adenocarcinoma from adenomatous polyp: A pathological correlation.

Colorectal cancer could be developed from adenomatous polyp. The study aimed to evaluate the diagnostic significance of stromal and epithelial CD10 (Neprilysin) expression in patients with colorectal adenocarcinoma and adenomatous polyps. This cross-sectional study was conducted on 141 patients with colorectal adenocarcinoma and adenomatous polyps referred to Ayatollah Rouhani Hospital from March 2020 to March 2021. Differential diagnoses of colorectal adenocarcinoma and adenomatous polyps were made colonoscopically, and then samples were taken from the lesions. The pathologists confirmed the final diagnosis as colorectal adenocarcinoma, high-grade or low-grade adenomatous polyps. The stromal and epithelial CD10 expression was evaluated by immunohistochemistry. The data was analyzed by SPSS 22 software (p<0.05). Sixty-five (46.1%) of the cases were low-grade polyps that were included positive (4 cases; 6.20%) and negative (61 cases; 93.80%) CD10 expression (P=0.001), also 76 (53.9%) of them were either high-grade polyps (21 cases) or adenocarcinomas (21 cases). Also, epithelial CD10 expression was significantly higher in the well-differentiated adenocarcinoma (38 cases) group than moderate (13 cases) and poor (4 cases) groups (P =0.001). Moreover, the CD10 expression level in the adenomatous polyps (10 positive cases and 76 negative cases) was correlated with the degree of dysplasia (P = 0.001) and the presence of tumor invasion (8 positive cases and 133 negative cases) (P = 0.001). The CD10 expression is associated with an increased degree of dysplasia and the presence of tumor invasion in patients with pre-neoplastic lesions and colorectal adenocarcinoma.

Stromal CD10 Expression in Invasive Breast Carcinoma in Correlation with ER, PR and Her2 Status and Tumor Grade.

Background: Increasing prevalence of breast cancer in our population is a leading cause of morbidity and mortality. Association of the tumor markers with the behavior of tumor cells may pave a way to better outcomes. Objectives: To investigate the frequency of Stromal CD10 expression in invasive breast carcinoma in correlation with ER, PR and Her2 status and tumor grade.Material and Methods: A total of 102 diagnosed cases of breast carcinoma who underwent mastectomies were examined. Immunohistochemistry was performed for Cluster of differentiation 10 (CD10), Estrogen receptor(ER) Progesterone receptor (PR) and Human epidermal receptor factor 2(HER2)for all the samples. Demographic characteristics and immunopathological variables were recorded. Results: Mean age of the participants was 54.05 ± 8.58 years. Immunohistochemical analysis revealed 83 (81.3%) cases as CD10 positive out of which 15 (14.7%) specimens were weak positive and 68 (66.6%) were strong positive. The expression of CD10 was significantly greater for patients with higher tumor grades (p-value 0.014). Significant association of stromal CD10 expression and ER negativity was observed (p-value &lt; 0.01). Out of 83 (81.3%) specimens that revealed positive CD10 expression, 64 (62.7%) were found HER2 positive and 19(18.6%) were HER2 negative signifying a positive correlation with p-value of &lt;0.01. Conclusion: Frequency of stromal CD10 expression is significantly associated with increasing tumor grade, HER2 positivity and ER negativity. It employs a prognostic role in predicting the aggressiveness of tumor as indicated by higher tumor grade and preemptive therapy with anti CD10 antibody may be beneficial in such candidates.Keywords: Breast carcinoma, CD10, ER, PR, HER2.

The Stromal Expression of CD-10 in Breast Carcinoma and its Association with Estrogen, Progesterone receptors, Her2Neu and Tumor Grade

The Stromal Expression of CD-10 in Breast Carcinoma and its Association with Estrogen, Progesterone receptors, Her2Neu and Tumor Grade

Abstract 3045: Role of CD10 negative stroma in the development of precursor lesion of endometriosis associated ovarian cancer

Abstract Introduction: Ovarian clear cell carcinoma (OCCC) is a rare, aggressive, chemo-resistant subtype of epithelial ovarian cancer, and is associated with a significantly worse five-year survival compared to other ovarian cancer types. This is in part due to its distinct cell of origin which is thought to arise within sites of endometriosis. Atypical endometriosis is considered a precursor lesion of endometriosis-associated ovarian cancers, including OCCC. However, the mechanism underlying the development of atypical endometriosis and subsequent malignant transformation is still unknown. We recently demonstrated the existence of a OCCC tumor-promoting mesenchymal stem cell (enMSCs), marked by the loss of CD10 expression, within the endometriotic microenvironment. Further, we demonstrated that CD10 negative enMSCs selectively enhance OCCC growth, but not high-grade serous ovarian cancer (HGSOC) growth which provides further evidence that the endometriotic microenvironment is uniquely supportive of OCCC tumorigenesis. Thus, we hypothesized that loss of stromal CD10 expression leads to the creation of the precursor microenvironment for OCCC. Methods: EnMSCs and endometriosis epithelial cells were isolated from endometriosis tissue. Tissues were collected from women who undergo surgery for benign endometriosis. Based on surface CD10 expression, enMSCs were divided into CD10 negative or positive populations. Endometriosis epithelium proliferation was assessed using in vitro assays. Long term organoid of CD10 negative enMSCs and endometriosis epithelium were implanted into NSG mice to assess tumor initiation capacity. Results: Our data showed that co-culture with CD10 negative enMSCs enhanced the proliferation of endometriosis epithelium. Further, CD10 negative enMSCs enhanced the sphere formation capacity (sphere number and sphere size) of endometriosis epithelial cells when compared to endometriosis epithelium co-cultured with CD10 positive enMSCs or cultured alone. Furthermore, long term growth of organoids containing CD10 negative enMSCs and endometriosis epithelium stimulated the development of cytologic atypia in the epithelial cells. Strikingly, these organoids, when injected into the fat pad of NSG mice, initiated localized tumors. In summary, our data highlighted the role of CD10 negative enMSCs in the development of cytologic atypia in endometriosis epithelium and inducing tumor formation in vivo. This work has the potential for significant clinical impact as identification of a stromal biomarker for OCCC development would have important implications in the clinical management of women with endometriosis, including determining the need for risk-reducing surgery. Further, this work has the potential to identify new targets to disrupt the unique microenvironment of OCCC, thus providing new therapeutic strategies for this deadly disease. Citation Format: Huda Issa Atiya, Lan Coffman. Role of CD10 negative stroma in the development of precursor lesion of endometriosis associated ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3045.

Stromal Expression of CD10 in Breast Carcinoma and Its Association with Known Prognostic Factors-A Tissue Microarray-Based Study.

Background Breast cancer is an epithelial malignancy; however, stroma plays a key role with its stimulatory and inhibitory factors in modulating tumor invasion and metastasis. CD10, a matrix metalloproteinase, is known to regulate cell adhesion, migration and helps in determining the progression of tumor. This knowledge helps to identify specific signals that promote growth, dedifferentiation, invasion, metastasis and serve as target for better therapeutic management. Objectives The aim of this study was to estimate frequency of expression of stromal CD10 and assess its prognostic significance in breast carcinomas by correlating with known prognostic factors. Materials and Methods Morphological parameters of 62 cases of carcinoma breast were studied on H&E (hematoxylin and eosin) stained sections and expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), and CD10 on manually constructed tissue microarray sections by immunohistochemistry (IHC). Staining pattern, percentage of stained cells, and intensity of stains were evaluated and IHC scoring of all markers was done. CD10 scores were correlated with the known prognostic factors (ER, PR, and HER2/neu). A p -value less than 0.05 was considered as significant. Results Stromal expression of CD10 was found in 82.3% of cases and it was significantly associated with increasing tumor size ( p = 0.012), increasing tumor grade ( p = 0.001), lymph node metastasis ( p = 0.018), necrosis ( p = 0.008), lymphovascular invasion ( p = 0.008), ER negativity ( p = 0.001), PR negativity( p = 0.007), HER 2 positivity ( p = 0.012), triple-negative molecular subtypes ( p = 0.001), and poor prognostic groups ( p = 0.01). Conclusion CD10 can be used as an independent prognostic stromal marker and this will help to envisage new therapeutic strategies.

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy.

Background: The therapeutic strategy of invasive breast cancer is based on routine histopathological markers (estrogen-, progesterone receptor, HER2, Ki67) routinely evaluated in tumor cells. However, the assessment of cancer stroma could influence therapeutic strategies. Studies have shown that stromal expression of CD10, a zinc-dependent metalloproteinase, is associated with biological aggressiveness of the tumor. In the present retrospective study, we aimed to evaluate stromal CD10 expression and association between CD10 expression and response to neoadjuvant chemotherapy in invasive breast cancer. Methods: CD10 immunohistochemistry was performed on core biopsies taken before the neoadjuvant therapy. Stromal CD10 expression was determined and compared with well-known predictive and prognostic tissue markers as well as with the following groups defined according to the degree of tumor response: no regression, partial regression, and complete regression. Results: A total of 60 locally advanced invasive breast carcinomas of "no special type" were included. The proportion of CD10 positive tumors was significantly higher in the "no regression" group compared to "complete regression" group (p = 0.000). Stromal CD10 expression was found to be significantly associated with decrease in response to neoadjuvant chemotherapy. According to CD10 expression we did not find any difference in hormone receptor status, Ki67, tumor grade or neostromal area. Conclusion: Our data suggest that CD10 expression can serve as a predictive marker of the effect of neoadjuvant chemotherapy in breast cancer patients. Therefore, its inclusion into the routine assessment of biopsies to tailor tumor-specific therapeutic strategies merits consideration.

Stromal CD10 expression in ameloblastomas: Correlation with clinical, radiographic and histopathologic characteristics

Objectives: To describe the clinical, radiographic and histopathologic features of ameloblastoma and analyze the relationship between CD10 expression in stromal cells of ameloblastoma and clinical, radiographic and histopathologic characteristics. Materials and methods: A cross-sectional study was performed on a total of 70 cases of ameloblastoma treated at the National Odonto-Stomatology Hospital at HCM city. Results: The male to female ratio was 1.12:1. The mean age of patients was 34.6 ± 14.8 years. The mean age was 30.5 ± 13.5 years for unicystic ameloblastoma and 36.8 ± 15.2 years for solid ameloblastoma. The location of ameloblastomas showed a marked predominance in the mandible (94.3%). Swelling was the most common symptom (92.9%). 18.6% had unilocular radiolucency and 81.4% had multilocular radiolucency. There were 47 cases of ill-defined edge (67.1%). The tumor was associated with embedded teeth in 17 cases (24.3%). Root resorption was evident in 47 of 61 (77.1%) and cortical perforation was presented in 41 of 70 (58.6%). The most frequent histological patterns in solid ameloblastoma were plexiform (28.9%) and in unicystic ameloblastoma were mural (48%). There were 39/70 cases which had CD10 possitive in stromal cells. Stromal CD10 positive expression in solid ameloblastomas (64,4%) was significantly higher than in unicystic ones (40%) (p&lt;0,05). There was statistically significant difference in tromal CD10 expression between multilocular and unilocular radiolucent ameloblastomas, between tumor with well-defined and ill- defined border, with and without cortical perforation (p&lt;0,05). Stromal CD10 expression showed no significant difference among different histological subtypes of solid/multicystic ameloblastomas. However, there was statistically significant correlation between stromal CD10 expression and histological subtypes of unicystic ameloblastomas. Conclusions: There were significant association between stromal CD10 expression and clinical, radiographic and histopathologic characteristics of ameloblastomas. Expression CD10 by stromal cells might be correlated to local invasion of ameloblastomas.

Stromal CD10 Expression in Breast Carcinoma and its Association with ER, PR, and HER2/neu Using Immunohistochemistry: A Cross-sectional Study

Introduction: Breast cancer is a common and deadly malignancy affecting women worldwide. Various immune markers, such as Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal growth factor Receptor 2 (HER2/neu), are commonly used to assess prognosis. Currently, ongoing research aims to evaluate molecular pathways that contribute to invasion and metastasis. One important immunomarker under investigation is CD10, a zinc-dependent Matrix Metalloproteinase (MMP) that degrades bioactive peptides. CD10 expression in the tumour stroma has been associated with the biological aggressiveness of several epithelial malignancies, including breast carcinoma. Aim: To analyse the association between stromal CD10 expression and different prognostic factors, such as age, histological grade, and status of ER, PR, and HER2/neu markers, in patients with breast cancer. Materials and Methods: This institutional-based, crosssectional study was conducted at the Department of Pathology, Nil Ratan Sircar Medical College and Hospital (NRSMC) in Kolkata, West Bengal, India over a period of one and a half years (February 2021 to July 2022). It included 120 cases of breast carcinoma diagnosed through histopathological examination of formalin fixed paraffin embedded sections, which were prepared from trucut biopsies and resection specimens referred from the Department of General Surgery, NRSMC. CD10 expression was assessed by Immunohistochemistry (IHC) in all cases and scored as negative, weak, or strong. The study examined the association between CD10 expression and the following parameters: age, histopathological grade, and the status of ER, PR, and HER2/neu markers. Data were entered into Microsoft Excel (MS) for statistical analysis. The significance of the study was determined using the Chi-square test, and data were analysed using Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM, Illinois, US). A p-value of &lt;0.05 was considered statistically significant. Results: The study included a total of 120 cases, with 119 cases of female breast cancer (99.16%) and one case of male breast cancer (0.84%). The mean±SD age of the patients was 54±5.038 years (range 44 to 67 years). The majority of cases 102 (85.00%) were diagnosed as Invasive Ductal Carcinoma (IDC), Not Otherwise Specified (NOS), followed by IDC-special types 18 (15.00%). CD10 expression was evaluated in all cases, and stromal CD10 positivity was observed in 79 out of 120 cases (65.80%), with 39 individuals (49.40%) showing weak positivity and 40 cases (50.60%) showing strong positivity. The remaining 41 cases (34.16%) were CD10 negative. Grade 3 cancers were predominant in this study 62 (51.66%). It was noted that CD10 stromal positivity increased with higher grade. Most of the cancers in this study were negative for ER, PR, and HER2/ Neu (78, 65.00%; 84, 70.00%; and 67, 55.83%, respectively). Stromal CD10 expression showed a significant association with ER (p-value=0.00001), HER2/neu (p-value=0.000089), tumour grade (p-value=0.0012), and an insignificant association with age (p-value0.264) and PR (p-value=0.256). Conclusion: Therefore, CD10 expression is strongly associated with well-established prognostic markers, namely higher tumour grade, HER2/neu negativity, and ER negativity. This indicates that CD10 can not only be used as an independent marker of poor prognosis but also as a target for the development of novel therapies.

Stromal microenvironment namely angiogenesis, tumor-infiltrating lymphocytes, and matrix metalloproteinase in invasive breast carcinoma: Do they have a prognostic role?

The role of stromal microenvironment in growth, invasiveness, and metastatic potential of breast carcinoma (BC) is being recognized increasingly, both to predict prognosis and as potential therapeutic targets. The present study aimed to evaluate the correlation of angiogenesis, tumor-associated lymphocytes, and stromal CD10 expression with clinicopathologic parameters. This study included 100 consecutive cases of invasive BC undergoing modified radical mastectomy. Relevant clinical details, pathological grade, lymph nodal status, and clinical stage were noted. Paraffin-embedded sections were subjected to immunohistochemistry for CD34, CD20, CD45RO, and CD10. Microvessel density (MVD), tumor-associated lymphocytes, and stromal CD10 expression were estimated from these sections. Statistical analysis was done using nonparametric tests to correlate the clinic-pathologic features with each of these parameters. MVD was found to be significantly higher in Grade III, node-positive cases, and higher stage breast cancers (P < 0.05). The number of T-lymphocytes was higher in node-positive cases, while B-lymphocytes were lower in number in higher grade tumors. CD10 expression showed a significant positive association with tumor grade, nodal status, and stage (P < 0.05 for each). This study demonstrates that changes in stromal microenvironment of BC such as MVD, tumor-associated lymphocytes, and stromal CD10 expression correlate with the clinicopathological parameters and hence may be exploited as prognostic markers or therapeutic targets, based on further larger studies.

O085 CD10 expression in carcinomas of the pancreas, bile duct and ampulla

Abstract Introduction Pancreatic cancer and cholangiocarcinoma including, cancer of ampulla of Vater, are very aggressive and have a dismal prognosis; hence improved methods of patient stratification are required. Methods We assessed the expression of CD10 in stromal and epithelial cells of two patient cohorts using immunohistochemistry on tissue microarrays. The first cohort was composed of 68 pancreatic adenocarcinomas and the second cohort was composed of 120 cancers of the bile duct and ampulla. Results In bile duct and ampullary carcinomas an association was observed between CD10 stromal expression and patient age (p =0.009). The CD10 stromal expression was associated with poor disease specific survival (DSS) (p =0.05). In multivariate Cox model for DSS, stromal CD10 expression (p = 0.037) was independently associated with poor outcome. In multivariate Cox model for disease free survival (DFS), CD10 stromal expression (p = 0.012), and nodal status (p = 0.025) were independently associated with poor outcome. In pancreatic cancer, no statistically significant association was observed between CD 10 stromal expression and clinicopathological variables such as tumour size (p = 0.099), T stage (p = 0.393), N stage (p = 0.860), Vascular invasion (p = 0.904), perineural invasion (p = 0.532) and grade (0.168). In multivariate Cox model for DSS, T stage (p = 0.042) was independently associated with poor outcome. Conclusion The results suggest that CD10 stromal expression may have prognostic significance in cholangiocarcinoma. The findings of this study warrant a larger follow-up study. Take-home message The results suggest that CD10 stromal expression may have prognostic significance in cholangiocarcinoma. The findings of this study warrant a larger follow-up study.

Stromal CD10 expression in gastric adenocarcinoma.

Gastric adenocarcinoma is a malignant neoplasm of the gastric mucosa composed of neoplastic cells and supporting stroma as with any neoplasm. Stromal myofibroblasts have an essential role in creating the tumor-promoting environment. They express certain substances, such as CD10. In this study, stromal CD10 expression was investigated by immunohistochemistry in gastric carcinoma, and its association with specific clinicopathological parameters was analyzed. Formalin-fixed paraffin-embedded blocks of 80 gastric adenocarcinoma cases were collected retrospectively in a private laboratory of the Rizgary Teaching Hospital for 2 years (January 2018–January 2020). Finally, the immunohistochemical study of CD10 expression in stromal cells was performed. According to the results, stromal CD10 immunoreactivity was detected in 15% of the cases. Furthermore, a statistically significant correlation was observed between stromal CD10 and the tumor type (P=0.015). However, no statistically significant relationship was identified between stromal CD10 expression and patients' age, gender, lymphovascular invasion, lymph node status, and tumor stage and grade. The results suggest a statistically significant positive correlation between stromal CD10 expression and tumor type.

CD10 expression in gastric adenocarcinoma and its correlation with histopathological features and lymph node metastasis

Background: Gastric cancer is one of the most common cancers worldwide. Invasion and metastasis are known prognostic factors. Previous studies have suggested CD10 expression in the epithelium and stroma of various carcinomas is associated with more aggressive behavior of the tumor. Aims and Objective: To study the immunohistochemical expression of CD10 in stromal cells of gastric adenocarcinoma and to correlate the expression with various clinicopathological features and lymph node metastasis. Materials and Methods: A cross sectional study of CD10 expression in 40 cases of gastric carcinoma in gastrectomy specimens was done. CD10 expression was correlated with age, gender, tumor site, tumor grade, histologic sub type, depth of invasion and lymph node status. Results: Out of 40 cases, 72.5% were males and 27.5% were females. Majority of cases were seen in 6th and 7th decades. Antrum was the most common location (70%) and intestinal morphology was the commonest histologic subtype (47.5%). Tumor size ranged from 2.5 to 11cms. 40% tumors were well differentiated. Majority (62.5%) of the tumors were in T3 stage. 25 (62.5%) cases showed a positive CD10 expression in stromal cells. Stromal CD10 expression in gastric carcinoma did not correlate with the age and gender of the cases as well as the location and size of the tumor, histologic subtype and lymph node involvement but correlated with depth of invasion (T stage) (p &lt;0.05). Conclusion: CD10 expression in gastric adenocarcinoma shows a significant correlation with depth of invasion. CD10 may be used as an immunohistochemical surrogate of tumor behavior.

Application of immunohistochemical staining of bcl-2, Ber-EP4, CD10, CK20, and Ki-67 in differential diagnosis between trichoblastoma and basal cell carcinoma

Objective: To study the utility of immunohistochemistry (IHC) in differential diagnosis between trichoblastoma (TB) and basal cell carcinoma (BCC). Methods: Fifty-eight cases of TB and 40 cases of BCC were collected at Fudan University Shanghai Cancer Center from January 2009 to December 2019 and retrospectively analyzed by IHC for bcl-2, Ber-EP4, CD10, CK20 and Ki-67. Fisher exact test was performed for statistical analysis. Results: Twenty-five (43.1%) TBs and 5 (12.5%) BCCs showed bcl-2 staining in the outermost layer of the epithelial nests, the difference was statistically significant (P<0.01). The proportion of cases with bcl-2 staining>75% of epithelial cells in BCC group was much higher than that in TB group (40% vs. 12.1%; P<0.01). BCC group showed larger proportions with Ber-EP4 staining>75%, 51%-75% of epithelial cells than TB group (12.5% vs. 1.7%, 37.5% vs. 8.6%;P<0.05). Fifty-five (94.8%) TBs demonstrated CD10 expression in the follicular stroma, while only 16 (40.0%) BCCs showed focal or scattered CD10 expression in reactive fibrous stroma (P<0.01). CK20 expression was present in 37 (63.8%) TBs with scattered pattern, but BCCs exhibited no CK20 staining except for only one case (2.5%) showing focal staining (P<0.01). Compared with TB group, the BCC group included more cases with Ki-67 labeling index ≥15% on average and ≥25% in hotspot areas (P<0.05). Conclusion: IHC is helpful in differential diagnosis between TB and BCC. Scattered CK20 staining pattern and stromal CD10 expression support the diagnosis of TB. Bcl-2 staining limited to the outermost layer of the proliferation is more likely to be found in TB. In contrast, Ber-EP4 positivity and higher Ki-67 labeling index tend to be present in BCC.

CD10 (neprilysin) expression: a potential adjunct in the distinction of hibernoma from morphologic mimics

Although the morphologic diagnosis of hibernoma is usually straightforward, some hibernomas have atypical morphologic features, mimicking atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLs). In addition, the multivacuolated brown fat cells may be mistaken for lipoblasts by pathologists, especially those without significant soft tissue tumor exposure. Thus, we continue to receive in consultation cases of hibernoma sent for MDM2 fluorescence in situ hybridizationtestingto exclude ALT/WDL. Testing hibernomas for MDM2 amplification, however, adds cost and delays the final diagnosis. Recently, we have noted expression of neprilysin (CD10, CALLA), a zinc-dependent metalloproteinase involved in the inactivation of various peptide hormones, in brown fat cells, and wished to explore the potential utility of this widely available, inexpensive ancillary test in the differential diagnosis of hibernoma. Formalin-fixed, paraffin-embedded tissue sections from well-characterized cases of hibernoma (n=48), brown fat (n=21), ALTs/WDLs (n=17), pleomorphic liposarcomas (PLPSs) (n=6), lipomas (n=5), and fat necrosis (n=5) were immunostained for CD10, using a commercially available antibody and routine laboratory protocols. CD10 expression was evaluated in both adipocytes and in surrounding stromal cells. The hibernomas occurred in 28 men and 20 women, ranging from 11 to 76 years of age and involved the extremities (n=25), pelvis (n=7), abdomen/pelvis/retroperitoneum (n=7), head and neck region (n=6), back (n=2), and chest (n=1). All showed diffuse, strong CD10 expression in multivacuolated brown fat cells and in the majority of adjacent univacuolated fat cells. Brown adipose tissue from various anatomic structures showed an identical pattern of immunoreactivity. In contrast, CD10 expression was present in the adipocytes of only 3 of 17 (18%) ALTs/WDLs and was absent in lipomas and fat necrosis. Lipoblasts expressed CD10 in 3 PLPSs. Expression of CD10 by surrounding fibroblastic stromal cells was more widespread, present in 13 hibernomas, 10 ALTs/WDLs, 1 instance of fat necrosis, 6 PLPSs, and 4 examples of brown fat. We conclude that immunohistochemistry for CD10 may represent a useful, rapid and inexpensive ancillary test in the differential diagnosis of hibernoma from potential morphologic mimics, especially when morphologic features favor hibernoma. CD10 expression in adipocytes, however, should be rigorously distinguished from fibroblastic stromal cell CD10 expression, a nonspecific finding.

Evaluation of stromal CD10 expression and its correlation with other clinico-pathological factors in invasive breast carcinoma

Evaluation of stromal CD10 expression and its correlation with other clinico-pathological factors in invasive breast carcinoma - IJPO- Print ISSN No: - 2394-6784 Online ISSN No:- 2394-6792 Article DOI No:- 10.18231/j.ijpo.2019.080, Indian Journal of Pathology and Oncology-Indian J Pathol Oncol

CD10 expression in gastric carcinoma is correlated with tumor grade and survival

BackgroundGastric carcinoma (GC) is the most common non-skin malignancy in Iranian men and the second leading cause of cancer-related mortality. Invasion and metastasis are considered as the major causes of cancer-related morbidity and mortality. Proteinases such as matrix metalloproteinases play an important role in tumor progression and mediating extracellular matrix remodeling. CD10 is a 90-110kd cell surface zinc-dependent metalloproteinase and there is evidence that this membrane protein may facilitate invasion and/or metastasis of tumoral cells. The objective of this study was to determine the frequency of CD10 expression in the stromal cells of GC and determine its relationship with survival and clinicopathological factors. MethodsA cross-sectional study was performed involving 50 patients with histopathologic diagnosis of GC. CD10 expression was determined by immunohistochemistry (IHC). Survival of the patients as well as the grade and stage of the tumors and demographic variables were documented. The Kaplan-Meier test was used for data analysis.ResultsStromal CD10 was detected in 46% of the GC stromal cells. No immunoreactivity was identified in the stromal cells of normal adjacent tissue. Stromal CD10 expression in gastric carcinoma did not correlate with the age and gender of the cases as well as the size and location of the tumor, and lymph node involvement but correlated with tumor stage (p=0.01), tumor grade(p=0.01) and patients’ survival (p=0.02). ConclusionStromal CD10 expression is correlated with tumor differentiation, clinical stage and survival in GC. CD10 expression could be considered as a negative prognostic factor for gastric carcinoma.

Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters.

Introduction:Breast cancer is the foremost cause of death in women worldwide with more than one million cases occurring annually.Aim:This study was conducted to study the stromal CD10 expression in breast carcinomas (BCa) and its correlation with various prognostic factors such as tumor size, histological grade, lymph node status, estrogen receptor (ER), progesterone receptor (PR), HER2neu, and Ki67 status.Materials and Methods:Sixty cases of BCa diagnosed between 2013 and 2015 were included in the study. Stromal expression of CD10 was studied on entire section of selected BCa blocks for all cases. A technique of manual tissue microarray was employed for the analysis of expression of immunohistochemical markers ER, PR, and HER2/Neu and Ki67 in all cases. Results were subjected to statistical analysis.Results:Stromal CD10 positivity was seen in 78.3% cases, out of which 53.3% of cases were strongly positive, and 25.0% cases were weakly positive. Positivity for ER, PR, HER2, and Ki67 was 31.7%, 33.3%, 65%, and 75%, respectively. Stromal expression of CD10 was found to be significantly associated with increasing tumor grade, lymph node status, HER2neu positivity, ER negativity, and Ki67 positivity. CD10 stromal expression was seen mainly in PR negative BCa cases; however, it was statistically insignificant. It was noted that CD10 stromal positivity increased with increasing grade.Conclusion:CD10 can be used as an independent prognostic marker and should be included in routine histopathology report. CD10 could act as a potential target for newer drug development.